Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Gynaecological cancers

2452 - A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)


20 Oct 2018


Poster Discussion session - Gynaecological cancers


Cytotoxic Therapy;  Immunotherapy

Tumour Site

Ovarian Cancer


Jung-Min Lee


Annals of Oncology (2018) 29 (suppl_8): viii332-viii358. 10.1093/annonc/mdy285


J. Lee1, C.M. Annunziata1, N. Houston1, E.C. Kohn1, S. Lipkowitz1, L. Minasian1, E. Nichols1, J. Trepel2, K. Trewhitt1, F. Zia1, A.D.S. Zimmer2

Author affiliations

  • 1 Women's Malignancies Branch, National Cancer Institute, 20814 - Rockville/US
  • 2 Developmental Therapeutics Branch, National Cancer Institute, 20814 - Rockville/US

Abstract 2452


The PARP inhibitor, olaparib (O) showed clinical activity in subsets of recurrent OvCa patients (pts). We hypothesized increased DNA damage by O may complement anti-tumor activity of immune checkpoint blockade, durvalumab (D) in recurrent OvCa. We previously reported the safety data and recommended phase 2 dose (RP2D) of D+O. Enrollment in the phase 2 OvCa cohort was completed April 2018 and results are presented here (NCT02484404).


Eligible pts with PS 0-1, good end organ function and biopsiable disease received the RP2D (O 300 mg orally twice daily and D 1500mg IV) on day 1 of each 28-day cycle. The primary objective was to estimate clinical activity using RECIST v1.1 response rate (RR) and a 2-stage design targeting 35 evaluable pts. Safety was assessed by CTCAEv4.0. Tissue and blood samples were collected pre-treatment and on therapy (cycle 1 day 15 and cycle 3 day 1).


35 pts received at least 1 cycle of treatment (median age 67 year-old [range 40-85], 6 germline BRCA mutation carriers [gBRCAm; 17%]/29 BRCA wild type [BRCAwt; 83%]). 30 pts (86%) had platinum-resistant recurrent disease. Median number of prior therapy regimens was 3.5 (1-16). Among 34 evaluable pts (6 gBRCAm/28 BRCAwt), 5 PRs were observed (15% RR, median 11months [6.5-23]): 2 pts with gBRCAm (platinum-resistant [8.5months] and -sensitive disease [11+months]) and 3 pts with BRCAwt (platinum-resistant [2; 23 and 14+months] and -sensitive disease [6.5months]). 13 pts (3 gBRCAm/10 BRCAwt) had SD > =4months (median 6.5months [4-12.5]), yielding 53% disease control rate (PR+SD > =4months). Grade 3/4 adverse events include anemia (26%) and lymphopenia (14%). 3 pts required O dose reduction due to grade 3 anemia (1), grade 3 atrial fibrillation (1) and recurrent grade 2 nausea refractory to supportive care (1). PD-L1 expression/TIL by immunohistochemistry, DNA repair deficiency by a BROCA-HR panel, and immune subsets by flow cytometry will be presented.


Our results suggested D+O was well-tolerated and had clinical activity in a subgroup of heavily pretreated BRCAwt OvCa pts. Biomarker evaluation is ongoing to further characterize the subset of pts who had benefit from D+O.

Clinical trial identification


Legal entity responsible for the study

The authors.


Center for Cancer Research/NCI by AstraZeneca/MedImmune under a Cooperative Research and Development Agreement between the Center for Cancer Research/NCI and AstraZeneca/MedImmune.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.